Western blots exhibited major downregulation of c-MYC protein upon C-KRAS-esiRNA and C-KRAS/PIK3CA-esiRNA treatment, but not C-PIK3CA-esiRNA treatment in DLD1 tumors (Fig 6A), whereas HT29 tumor reacted to treatment in a different manner. This evidence concerns the gene KRAS and neoplasm.